Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Coloplast develops products and services that make life easier for people with ver...
Coloplast develops products and services that m...
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autolog...
BrainStorm (NASDAQ:BCLI) is a biotechnology com...
Eidos is a clinical stage biopharmaceutical company focused on addressing the larg...
Eidos is a clinical stage biopharmaceutical com...
Titan is a specialty pharmaceuticals company that develops therapeutics for select...
Titan is a specialty pharmaceuticals company th...
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on ...
Organogenesis Holdings Inc. is a leading regene...
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
Join the National Investor Network and get the latest information with your interests in mind.